Table 3.
Adverse reactions in the RIT and CIT groups.
| Adverse reactions | RIT (n=40) | CIT (n=70) | ||
|---|---|---|---|---|
| Events, n (% of total injections) | Patients, n (%) | Events, n (% of total injections) | Patients, n (%) | |
| LR | ||||
| 23 (2.13%) | 6 (15.00%) | 27 (1.54%) | 9 (12.86%) | |
| SR | ||||
| Grade I | 4 (0.37%) | 3 (7.50%) | 7 (0.40%) | 5 (7.14%) |
| Grade II | 2(0.19%) | 2(5.00%) | 1(0.06%) | 1(1.43%) |
| Grade III | 0 | 0 | 0 | 0 |
| Grade IV | 0 | 0 | 0 | 0 |
No significant differences in rates of LRs and SRs between the 2 groups (p > 0.05) RIT, rush subcutaneous immunotherapy+1 dose of anti-IgE combination; CIT, conventional allergen immunotherapy; LR, local reaction; SR, systemic reaction.